Jiayue Ding

Dr. Jiayue Ding


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2018 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
DZDa Zhou
Da Zhou
JDJiayue Ding
Jiayue Ding
JYJing‐Yuan Ya
Jing‐Yuan Ya
LPLi‐Qun Pan
Li‐Qun Pan
FYFeng Yan
Feng Yan
Ran MengRan Meng
Ran Meng

15 November 2017 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
DZDa Zhou
Da Zhou
Ran MengRan Meng
Ran Meng
SLSi‐Jie Li
Si‐Jie Li
JYJing‐Yuan Ya
Jing‐Yuan Ya
JDJiayue Ding
Jiayue Ding
Xunming JiXunming Ji
Xunming Ji

31 July 2023 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
JDJiayue Ding
Jiayue Ding
XYXuanye Yue
Xuanye Yue
XTXiaobing Tian
Xiaobing Tian
ZLZhangyuan Liao
Zhangyuan Liao
Ran MengRan Meng
Ran Meng
MZMing Zou
Ming Zou
Background: Venous thromboembolism (VTE) is a common thrombotic vascular disease that has a significant impact on people’s well-being and quality of life. A plethora of clinical studies explore the relationship between inflammatory biomarkers and VTE but yield conflicting results. This article proposed to pool these studies to draw a more convincing conclusion. Methods: We searched several databases for studies before April 2023. Available data was processed using Stata software (version 15.0 SE) and R (version 4.1.2). This meta-analysis has been registered in PROSPERO (CRD42022321815). The VTE in this review encompassed pulmonary embolism, deep vein thrombosis, and cerebral venous thrombosis. Results: A total of 25 articles were finally involved in this study. Our results revealed that higher levels of high-sensitivity C-reactive protein (hs-CRP, MD, 0.63, 95%CI, 0.21—1.05) and C-reactive protein (CRP)> 3ug/ml (OR, 1.52, 95%CI, 1.18—1.96) might be regarded as risk factors for future VTE occurrence. The elevated levels of monocyte (MD, 0.03, 95%CI, 0.00—0.05), hs-CRP (0.85, 0.61—1.08), CRP (0.66, 0.20—1.13) and IL-6 (0.47, 0.25—0.70) might represent the previous VTE; a series of markers such as white blood cell (1.43, 0.88—1.98), neutrophil (1.79, 1.02—2.56), monocyte (0.17, 0.14—0.21), hs-CRP (3.72, 1.45—5.99), IL−6 (5.99, 4.52—7.46), platelet-lymphocyte ratio (33.1, 24.45—41.78) and neutrophil-lymphocyte ratio (1.34, 0.95—1.73) increased during the acute phase of VTE. Conclusions: In general, activated inflammatory biomarkers might not only be correlated with an increased risk of VTE, but may also give a hint of the occurrence of VTE in clinical settings.

22 May 2019 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
JDJiayue Ding
Jiayue Ding
DZDa Zhou
Da Zhou
LPLi‐Qun Pan
Li‐Qun Pan
JYJing‐Yuan Ya
Jing‐Yuan Ya
CLCheng Liu
Cheng Liu
Ran MengRan Meng
Ran Meng
Aims: This study aimed to identify the clinical profiles of cervical spondylosis‐related internal jugular vein stenosis (IJVS) comprehensively.Methods: A total of 46 patients, who were diagnosed as IJVS induced by cervical spondylotic compression were recruited. The clinical manifestations and imaging features of IJVS were presented particularly in this study.Results: Vascular stenosis was present in 69 out of the 92 internal jugular veins, in which, 50.7% (35/69) of the stenotic vessels were compressed by the transverse process of C1, and 44.9% (31/69) by the transverse process of C1 combined with the styloid process. The transverse process of C1 compression was more common in unilateral IJVS (69.6% vs 41.3%, P = 0.027) while the transverse process of C1 combined with the styloid process compression had a higher propensity to occur in bilateral IJVS (52.2% vs 30.4%, P = 0.087). A representative case underwent the resection of the elongated left lateral mass of C1 and styloid process. His symptoms were ameliorated obviously at 6‐month follow‐up.Conclusions: This study proposes cervical spondylotic internal jugular venous compression syndrome as a brand‐new cervical spondylotic subtype. A better understanding of this disease entity can be of great relevance to clinicians in making a proper diagnosis.

30 March 2018 in Neurological Research
Verified
Journal Article
Closed access
JDJiayue Ding
Jiayue Ding
DZDa Zhou
Da Zhou
MSMeng Sui
Meng Sui
Ran MengRan Meng
Ran Meng
ACAnkush Chandra
Ankush Chandra
Xunming JiXunming Ji
Xunming Ji
Background Normobaric oxygen (NBO) has received considerable attention due to controversial data in brain protection in patients with acute stroke. This study aims to analyze current data of NBO on brain protection as used in the clinic. Methods We searched for and reviewed relevant articles and references from Pubmed, Medline, Embase, Cochrane, and Clincialtrials.gov that were published prior to October 2017. Data from prospective studies were processed using RevMan5.0 software, provided by Cochrane collaboration and transformed using relevant formulas. Results A total of 11 prospective RCT studies including 6366 patients with acute stroke (NBO group, 3207; control group, 3159) were enrolled in this analysis. △NIHSS represented the values of NIHSS at 4, 24 h, or 7 days post-stroke minus baseline NIHSS. Compared to controls, there was a minor trend toward NBO benefits in short-term prognostic indices, as indicated by decreased ΔNIHSS at our defined time points. By contrast, NBO decreased Barthel Index scores between 3 and 7 months, and increased death rates at 3, 6 months, and 1 year, whereas, modified Rankin Scale scores between 3 and 6 months were unchanged. Conclusions The existing trends toward benefits revealed in this meta-analysis help us appreciate the promising value of NBO, although current evidence of NBO on improving clinical outcomes of stroke is insufficient. Well-designed multi-center clinical trials are encouraged and urgently needed to further explore the efficacy of NBO on brain protection.

1 September 2018 in World Neurosurgery
Verified
Journal Article
Closed access
JDJiayue Ding
Jiayue Ding
DZDa Zhou
Da Zhou
ECEric Eugene Paul Cosky
Eric Eugene Paul Cosky
LPLiqun Pan
Liqun Pan
JYJingyuan Ya
Jingyuan Ya
Ran MengRan Meng
Ran Meng